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1. INTRODUCTION {#pca2882-sec-0006}
===============

Lonicerae Japonicae Flos (LJF) and Lonicerae Flos (LF), commonly known as Jin‐yin‐hua and shan‐yin‐hua in China, respectively, are traditional Chinese medicines (TCMs) with widespread use in the medicine industry. More than 500 prescriptions contain LJF for treatment of carbuncles, furuncles, erysipelas, sores, swelling and affections caused by exopathogenic wind‐heat, epidemic febrile diseases at the early period.[1](#pca2882-bib-0001){ref-type="ref"} Modern pharmacological research has confirmed its high medicinal value, such as anti‐inflammatory,[2](#pca2882-bib-0002){ref-type="ref"}, [3](#pca2882-bib-0003){ref-type="ref"}, [4](#pca2882-bib-0004){ref-type="ref"} anti‐bacterial,[5](#pca2882-bib-0005){ref-type="ref"} anti‐oxidant,[6](#pca2882-bib-0006){ref-type="ref"} hepatoprotective,[7](#pca2882-bib-0007){ref-type="ref"} anti‐viral[8](#pca2882-bib-0008){ref-type="ref"} and other biological activities. Meanwhile, clinical practice in recent years also showed LJF possesses a preventive effect on the severe acute respiratory syndrome (SARS) virus and H1N1 influenza virus.[9](#pca2882-bib-0009){ref-type="ref"}, [10](#pca2882-bib-0010){ref-type="ref"} In China, there is a notion of "Let food be thy medicine and medicine be thy food". LJF and LF also have been used to make tea, food, and beverages due to their heat‐clearing and health care properties.

LJF and LF have been documented as independent projects according to plant morphology, medicinal properties and chemical composition in Chinese Pharmacopoeia since 2005. *Lonicera japonica* Thunb. is determined as the only plant source of LJF. Whereas, LF has four sources of germ plasm including *Lonicera macranthoides* Hand.‐Mazz., *L. hypoglauca* Miq., *L. confusa* DC. and *L. fulvotomentosa* Hsu et S.C. Cheng in current Chinese Pharmacopoeia. They are typical Chinese medicines of "heterologous effect". Numerous literature has reported that LF has similar pharmacological activities as LJF,[8](#pca2882-bib-0008){ref-type="ref"}, [11](#pca2882-bib-0011){ref-type="ref"} only with a marginal difference in the strength of the drug effect. But until now, there is still no recognised theory to explain this phenomenon. Therefore, owing to the close proximity of plant species, the similar appearance and function, the quality standards and mutual substitution of LF and LJF still remain controversial.

Chemical composition is the basis of the pharmacological action of medicinal materials. In recent years, phytochemical studies have revealed that more than 200 components have been identified from *L. japonica*, its main constituents include essential oils, flavonoids, organic acid, iridoids and saponins,[12](#pca2882-bib-0012){ref-type="ref"}, [13](#pca2882-bib-0013){ref-type="ref"} which modulate multiple functions. For instance, the volatile oil possesses antifungal activity; flavonoids and organic acid have strong inhibitory activity against multiple pathogens,[14](#pca2882-bib-0014){ref-type="ref"} anti‐oxidant, and anti‐tumour;[15](#pca2882-bib-0015){ref-type="ref"} iridoids and saponins also have shown excellent activity of anti‐tumour, anti‐inflammation, antioxidant and hepatoprotective;[16](#pca2882-bib-0016){ref-type="ref"} amino acid is an essential nutrient that is beneficial to human body; it exhibits a variety of physiological activities, including anti‐platelet aggregation, antioxidant and immunity enhancement;[17](#pca2882-bib-0017){ref-type="ref"} nucleosides are the major components of nucleic acids. Some nucleosides and their derivatives have significant physiological functions, for example inosine can be used to treat acute and chronic hepatitis, rheumatic heart disease.[18](#pca2882-bib-0018){ref-type="ref"} Therefore, it is certain that excellent clinical efficacy arises from the synergistic effects of complicated chemical components. In Chinese Pharmacopoeia 2015 edition, chlorogenic acid and luteoloside have been used as biomarkers to characterise the quality of LJF. Notably, some other medicinal plants have also been found to contain high contents of chlorogenic acid and luteoloside, and to determine single or several bioactive compounds in herbal medicines is one‐sided with respect to the wholeness of TCM meaning multi‐components at multi‐targets. Only chlorogenic acid and luteoloside might not completely inflect the quality of LJF, and owing to the mixing of different medicinal parts, unconsciously mislabelled or confused of LJF and LF, the quality and safety of LJF and LF cannot be guaranteed. Therefore, an effective and reliable method is necessary to be established to evaluate the quality of LJF and LF. Meanwhile, it is meaningful to find the distinguishing chemical markers and identify which part (the flower bud or the flower) is the optimum quality of LJF.

Many methodologies have been reported to control the quality of LJF and LF. For instance, high‐performance liquid chromatography with ultraviolet detector (HPLC‐UV) was used for determination of phenolic acid;[19](#pca2882-bib-0019){ref-type="ref"}, [20](#pca2882-bib-0020){ref-type="ref"}, [21](#pca2882-bib-0021){ref-type="ref"} HPLC with evaporative light scattering detector (HPLC‐ELSD) was employed for quantitative saponins and iridoid glucosides.[22](#pca2882-bib-0022){ref-type="ref"}, [23](#pca2882-bib-0023){ref-type="ref"}, [24](#pca2882-bib-0024){ref-type="ref"} Nevertheless, the earlier methods only could detect an individual active ingredient which made the assay less efficient. HPLC‐diode array detector (DAD)‐ELSD[25](#pca2882-bib-0025){ref-type="ref"}, [26](#pca2882-bib-0026){ref-type="ref"} was reported to detect flavonoids, iridoids, phenolic acids, and saponins in LJF and LF. However, there are still several shortcomings such as the relatively low sensitivity of ELSD and the inaccuracy of chromatographic peaks only determined by retention time. With the development of analytical technology, HPLC‐DAD‐electrospray ionisation mass spectrometry (ESI‐MS) was proposed to analyse multiple types of bioactive constituents.[27](#pca2882-bib-0027){ref-type="ref"}, [28](#pca2882-bib-0028){ref-type="ref"} It has been reported that HPLC‐ESI‐time‐of‐flight (TOF)‐MS was used to quantify 32 bioactive compounds in Lonicera species.[29](#pca2882-bib-0029){ref-type="ref"} But these methods mainly focus on quantification. Nowadays, ultra‐fast liquid chromatography‐tandem triple quadrupole mass spectrometry (UFLC‐QTRAP‐MS/MS) has been used to identify the content of TCM due to its high sensitivity and informativity.[30](#pca2882-bib-0030){ref-type="ref"}, [31](#pca2882-bib-0031){ref-type="ref"}

In the present article, we attempted to develop a comprehensive and reliable method of UFLC‐QTRAP‐MS/MS coupled with multivariate statistical analysis for the quality evaluation of LJF and LF. This method could simultaneously detect 50 constituents, including 12 organic acids, 12 flavonoids, 6 iridoids, 3 saponins, 13 amino acids and 4 nucleosides in 35 batches of LJF and LF samples from different habitats and commercial herbs. Moreover, principal component analysis (PCA) and partial least squares discriminant analysis (PLS‐DA) was performed to distinguish the LJF and LF. Grey relational analysis (GRA) was introduced to assess the quality of LJF and LF according to the contents of the tested constituents. Our study not only established a method of simultaneous determination of multiple bioactive constituents of LJF and LF, but provided comprehensive information on the quality control of them. The developed method is conducive to distinguish orthologues or paralogues of them, and provide the support for "heterologous effects". To the best of our knowledge, our study is the most comprehensive methodology on the quantitative comparative analysis of LJF and LF, which has a high scientific and reference value.

2. MATERIALS AND METHODS {#pca2882-sec-0007}
========================

2.1. Chemicals, reagents, and materials {#pca2882-sec-0008}
---------------------------------------

Fifty chemical standards including chlorogenic acid (**1**), neochlorogenic acid (**2**), cryptochlorogenic acid (**3**), 3,5‐*O*‐dicaffeoylquinic acid (**4**), 3,4‐*O*‐dicaffeoylquinic acid (**5**), 4,5‐*O*‐dicaffeoylquinic acid (**6**), 1,3‐*O*‐dicaffeoylquinic acid (**7**), caffeic acid (**8**), quinic acid (**9**), protocatechuic acid (**10**), ferulic acid (**11**), 4,5‐*O*‐dicaffeoylquinic acid methyl ester (**12**), rutin (**13**), hyperoside (**14**), luteoloside (**15**), luteolin (**16**), rhoifolin (**17**), diosmetin (**18**), apigenin (**19**), kaempferol (**20**), astragalin (**21**), lonicerin (**22**), kaempferol‐3‐*O*‐rutinoside (**23**), isoquercitrin (**24**), sweroside (**25**), secologanic acid (**26**), loganin (**27**), secoxyloganin (**28**), loganin acid (**29**), morroniside (**30**), macranthoidin A (**31**), dipsacoside B (**32**), akebia saponin D (**33**), [l]{.smallcaps}‐alanine (**34**), [l]{.smallcaps}‐serine (**35**), [l]{.smallcaps}‐proline (**36**), [l]{.smallcaps}‐valine (**37**), [l]{.smallcaps}‐threonine (**38**), [l]{.smallcaps}‐isoleucine (**39**), [l]{.smallcaps}‐leucine (**40**), [l]{.smallcaps}‐aspartic acid (**41**), [l]{.smallcaps}‐glutanmate (**42**), [l]{.smallcaps}‐lysine (**43**), [l]{.smallcaps}‐histidine (**44**), [l]{.smallcaps}‐phenylalanine (**45**), [l]{.smallcaps}‐arginine (**46**), cytidine (**47**), uridine (**48**), adenosine (**49**) and inosine (**50**) were detected in this experiment. The purity of all standard components was more than or equal to 98%. The structures of the standard substances are shown in Supporting Information Figure [S1](#pca2882-supitem-0001){ref-type="supplementary-material"}. Among them, **9**, **13**, **14**, **21** and **24** were purchased from the Control of Pharmaceutical and Biological Products (Beijing, China); **18**--**20**, **23**, **25** and **33** were offered by Chengdu Chroma Biotechnology Co. Ltd (Sichuan, China); **1**--**5**, **8**, **11**, **27** and **34**--**50** were obtained from Shanghai Yuanye Biotechnology Co. Ltd (Shanghai, China); **6**, **7** and **10** were received from Chengdu Prefa Technology Development Co. Ltd (Sichuan, China); **12**, **15**--**17**, **22**, **26**, and **29**--**31** were provided by Liangwei Chemical Reagent Co. Ltd (Nanjing, China); **28** and **32** were acquired from Nanjing Jingzhu Biotechnology Co. Ltd (Nanjing, China).

In the experiment, chromatographic grade methanol and acetonitrile were purchased from Merck (Darmstadt, Germany); other analytical grade solvents were purchased from Liangwei Chemical Reagent Co. Ltd. Ultrapure water was obtained in Milli‐Q purifying system (Millipore, Bedford, MA, USA); samples were collected in 2018, samples 1--10 are LF (*Lonicera macranthoides* Hand.‐Mazz.), samples 11--21 are flower buds of Lonicerae Japonicae and samples 22--35 are flowers of Lonicerae Japonicae. Detailed information on these samples is listed in Table [1](#pca2882-tbl-0001){ref-type="table"}. The botanical origins of the materials were identified by one of our authors, Professor Xunhong Liu. Voucher specimens were deposited in the Herbarium of Pharmacy, Nanjing University of Chinese Medicine, China.

###### 

Information of Lonicerae Japonicae Flos (LJF) and Lonicerae Flos (LF)

  Species                                                 Sample number   Batch number   Habits                                                         Origin
  ------------------------------------------------------- --------------- -------------- -------------------------------------------------------------- -------------------
  Lonicerae Flos (*Lonicera macranthoides* Hand.‐Mazz.)   1               2018110306     Hunan                                                          Shaodong Lianqiao
  2                                                       20181103061     Hunan          Shaodong Lianqiao                                              
  3                                                       2018110701      Hunan          Longhui                                                        
  4                                                       20181107011     Hunan          Longhui                                                        
  5                                                       2018110305      Shanxi         Shangluo Danfeng                                               
  6                                                       20181103051     Shanxi         Shangluo Danfeng                                               
  7                                                       2018110308      Hunan          Shaodong Lianqiao                                              
  8                                                       20181103081     Hunan          Shaodong Lianqiao                                              
  9                                                       2018110703      Hunan          Longhui                                                        
  10                                                      20181107031     Hunan          Longhui                                                        
  Lonicerae Japonicae Flos                                11              20181108       Shandong                                                       Local collection
  12                                                      2018110302      Hebei          Juluxian Gouqijinyinhua market                                 
  13                                                      2018110506      Henan          Fengqiu                                                        
  14                                                      2018110502      Shandong       Linyi                                                          
  15                                                      180401          Henan          Anhui YaoZhiyuan TCM decoction co., ltd.                       
  16                                                      2018110603      Henan          Fengqiu                                                        
  17                                                      2018110604      Henan          Fengqiu                                                        
  18                                                      C16011901       Shandong       Zhejiang Yetongren pharmaceutical co., ltd.                    
  19                                                      2018110503      Shandong       Linyi                                                          
  20                                                      20181106011     Henan          Fengqiu                                                        
  21                                                      20181106012     Henan          Fengqiu                                                        
  22                                                      2018110505      Shandong       Linyi                                                          
  23                                                      2018110302      Hebei          Juluxian Gouqijinyinhua market                                 
  24                                                      20181103021     Hebei          Juluxian Gouqijinyinhua market                                 
  25                                                      20181103022     Hebei          Juluxian Gouqijinyinhua market                                 
  26                                                      2018110301      Hebei          Juluxian Gouqijinyinhua market                                 
  27                                                      1803151         Shandong       Suzhou Boyuan pharmaceutical industry                          
  28                                                      20181103011     Hebei          Juluxian Gouqijinyinhua market                                 
  29                                                      2018110504      Shandong       Linyi                                                          
  30                                                      20181109                       Local collection                                               
  31                                                      2018110303      Hebei          Juluxian Gouqijinyinhua market                                 
  32                                                      20181107        Shandong       Local herbal medicine market                                   
  33                                                      170802          Shandong       Bozhou Beshixin traditional Chinese medicine slice co., ltd.   
  34                                                      20181106        Shandong       Local herbal medicine market                                   
  35                                                      171116          Shandong       Shanghai medicine holdings Yixing co., ltd.                    

Samples 1--10 are LF (*Lonicera macranthoides* Hand.‐Mazz.); samples 11--21 are Flower buds Lonicerae Japonicae; samples 22--35 are Flowers Lonicerae Japonicae.

2.2. Preparation of standard solutions {#pca2882-sec-0009}
--------------------------------------

Fifty standard substances were prepared by dissolving in 70% methanol, and their concentrations were as follows: (**1**) 10.05 mg/mL, (**2**) 1.04 mg/mL, (**3**) 5.13 mg/mL, (**4**) 1.24 mg/mL, (**5**) 1.01 mg/mL, (**6**) 10.09 mg/mL, (**7**) 10.06 mg/mL, (**8**) 5.05 mg/mL, (**9**) 0.99 mg/mL, (**10**) 10.01 mg/mL, (**11**) 1.02 mg/mL, (**12**) 1.05 mg/mL, (**13**) 1.33 mg/mL, (**14**) 1.04 mg/mL;, (**15**) 1.01 mg/mL, (**16**) 5.09 mg/mL, (**17**) 1.28 mg/mL, (**18**) 1.02 mg/mL, (**19**) 1.05 mg/mL, (**20**) 1.00 mg/mL, (**21**) 1.17 mg/mL, (**22**) 1.01 mg/mL, (**23**) 1.01 mg/mL, (**24**) 1.01 mg/mL, (**25**) 5.08 mg/mL, (**26**) 5.04 mg/mL, (**27**) 5.08 mg/mL, (**28**) 5.07 mg/mL, (**29**) 5.07 mg/mL, (**30**) 5.10 mg/mL, (**31**) 5.04 mg/mL, (**32**) 10.09 mg/mL, (**33**) 4.99 mg/mL, (**34**) 5.09 mg/mL, (**35**) 5.09 mg/mL, (**36**) 5.09 mg/mL, (**37**) 1.32 mg/mL, (**38**) 1.06 mg/mL, (**39**) 1.03 mg/mL, (**40**) 1.06 mg/mL, (**41**) 1.04 mg/mL, (**42**) 1.07 mg/mL, (**43**) 1.00 mg/mL, (**44**) 1.00 mg/mL, (**45**) 1.01 mg/mL, (**46**) 1.01 mg/mL, (**47**) 1.38 mg/mL, (**48**) 0.68 mg/mL, (**49**) 1.03 mg/mL, (**50**) 1.59 mg/mL. The mixed standard stock solution containing 50 standard substances was serially diluted with 70% (*v*/*v*) methanol to require concentrations for the establishment of the calibration curves. All solutions were stored at 4°C, and then filtered through 0.22 μm membranes (Jinteng laboratory equipment, Tianjin, China) before analysis.

2.3. Preparation of sample solutions {#pca2882-sec-0010}
------------------------------------

All of the samples were pulverised and sieved through the 50‐mesh. The accurately weighed powder (1.0 g) was extracted by ultrasonication in 40 mL 70% methanol for 45 min, then cooled at room temperature; the same solution was used to replenish the extraction system upon solvent loss because of volatilisation. The mixture was centrifuged at 12000 rpm for 10 min, then filtered through a 0.22 μm membrane prior to analysis.

2.4. UFLC‐QTRAP‐MS/MS instrumentation and conditions {#pca2882-sec-0011}
----------------------------------------------------

All samples were analysed using UFLC system (SHIMADZUDGU Corp., Kyoto, Japan) with a triple quadrupole‐linear ion trap mass spectrometer (QTRAP‐5500) (AB SCIEX, Framingham, MA, USA). The separation was performed using the X Bridge ®C~18~ (4.6 mm × 100 mm, 3.5 μm) (Waters, Wexford, Ireland). The mobile phase was composed of 0.2% aqueous formic acid (A) and acetonitrile with 0.2% formic acid (B) at the flow rate of 0.8 mL/min. The gradient elution as follows: 0--5 min: 2% B; 5--10 min: 2--13% B; 10--12 min: 13% B; 12--17 min: 13--25% B; 17--25 min: 25--33% B; 25--27 min: 33--35% B; 27--29 min: 35--50% B; 29--31 min: 50--95% B. The re‐equilibration time was 4 min, and the injection volume was 1 μL. The ESI‐MS spectra were acquired in the multiple reaction monitoring (MRM) mode under both positive and negative ion modes. The conditions for the ESI‐MS analysis were set as follows: pressure of nebuliser of MS, 4500 V (positive) and −4500 V (negative); gas temperature 550°C; GS1 flow 55 L/min; GS2 flow 55 L/min; CUR flow 40 L/min; all MS data were analysed by the Analyst 1.6.2 software (AB SCIEX, Framingham, MA, USA).

2.5. Validation of UFLC‐QTRAP‐MS/MS method {#pca2882-sec-0012}
------------------------------------------

The proposed method was validated according to linearity and range, the limit of detection (LOD), limit of quantitation (LOQ), precision (intra‐day and inter‐day), repeatability, stability, accuracy, and matrix effect. The mixed standard stocked solution containing 50 reference substances were serially diluted with 70% methanol to require concentrations for the establishment of calibration curves. The LODs and LOQs of these analytes under the present chromatographic conditions were determined at signal‐to‐noise (S/N) ratio equalled to 3 and 10, respectively. Precision was evaluated by injecting six replicates the same sample solution within one day and three days. Six independent sample solutions from the same sample were analysed to ensure the repeatability. The same sample solution was injected at 0, 2, 4, 8, 12, and 48 h to evaluate the stability of the instrument. A recovery test was used to check the accuracy of the method. The matrix effect was evaluated by the slope (slope matrix/slope solvent) comparison method.[32](#pca2882-bib-0032){ref-type="ref"}

2.6. Multivariate statistical analysis {#pca2882-sec-0013}
--------------------------------------

PCA is used to visualise similarities or differences in multivariate data, which is an unsupervised pattern recognition technique. It is a method to pass multiple variables through a linear transformation to select fewer important variables and has been widely used in the differentiation and identification of medicinal materials. In order to observe the classification of LJF and LF, the data of 50 analytes were used to carry out PCA using SIMCA‐P 13.0 software (version 13.0, Umetrics AB, Umea, Sweden).

To find out the different chemical composition between JLF and JF, supervised PLS‐DA was performed by SIMCA‐P 13.0 software (version 13.0, Umetrics AB).

GRA is an effective and quantitatively comparative analysis method, which uses grey correlation degree to describe the strength, size, and order of the relationship between factors based on the sample data of each factor. It was introduced to assess the quality of LJF and LF based on the contents of 50 analytes by calculating the relative correlation degree of each sample.

3. RESULTS AND DISCUSSION {#pca2882-sec-0014}
=========================

3.1. Optimisation of extraction conditions {#pca2882-sec-0015}
------------------------------------------

In order to obtain quantitative extraction, various factors are utilised and optimised including extraction solvent (100% (*v*/*v*) methanol, 70% (*v*/*v*) methanol, 25% (*v*/*v*) methanol), time (60 min, 45 min, 20 min), method (ultrasonic and refluxing), and the solvent‐to‐sample ratios (100:1, 40:1, 25:1 (*v*/*w*)). The results showed that the extraction efficiency of samples in 70% (*v*/*v*) methanol solution at room temperature is optimal, and suitable solvent‐to‐sample ratio and ultrasonic time were 40:1 and 45 min, respectively.

3.2. Optimisation of UFLC‐QTRAP‐MS/MS conditions {#pca2882-sec-0016}
------------------------------------------------

Chromatographic conditions were optimised. Four common important parameters including three types of columns \[X Bridge ®C~18~ (4.6 mm × 100 mm, 3.5 μm), Agilent ZORBAX SB C~18~ column (250 mm × 4.6 mm, 5 μm) (Agilent, Palo Alto, CA, USA), Thermo Acclaim TM RSLC 120 C~18~ (150 mm × 2.1 mm,2.2 μm) (Thermo Scientific, Waltham, MA, USA)\], different mobile phases (water/acetonitrile, water/methanol, 0.1% aqueous formic acid/acetonitrile, 0.2% aqueous formic acid/0.2% formic acid acetonitrile), flow rate (0.3 mL/min, 0.8 mL/min, 1.0 mL/min), and column temperatures (25, 30, and 35°C) were investigated. Considering the strong hydrophilicity of organic acids, amino acids and nucleosides, the column of X Bridge ®C~18~ (4.6 mm × 100 mm, 3.5 μm) was chosen. Water/acetonitrile system showed more powerful resolution than water/methanol system. Furthermore, when the mobile phase was added with formic acid, the shape and symmetry of chromatographic peak of organic acids were significantly improved. In addition, the column temperature also affects the chromatographic separation. As a result, 0.2% aqueous formic acid/0.2% formic acid acetonitrile at the flow rate of 0.8 mL/min at 30°C on X Bridge ®C~18~ (4.6 mm × 100 mm, 3.5 μm) was selected and applied.

In order to effectively distinguish isomers by high resolution mass spectrometry and secondary mass spectrometry fragments, the individual solutions of all standard compounds (100 ng/mL in 70% (*v*/*v*) methanol) were injected into the ESI source in the positive and negative ion modes to get more suitable de‐clustered voltage (DP) and collision energy (CE) parameters. The most abundant fragment ions were chosen as MRM transition from MS/MS spectrum; after trial and error inspection, most constituents had a good response in the negative ion mode; only kaempferol‐3‐*O*‐rutinoside, amino acids, and nucleosides respond better in positive ion mode. Optimal values of 50 analytes are summarised in Table [2](#pca2882-tbl-0002){ref-type="table"} and the chromatograms with MRM mode are presented in Figure [1](#pca2882-fig-0001){ref-type="fig"}. However, as shown in Table [2](#pca2882-tbl-0002){ref-type="table"} chlorogenic acid, neochlorogenic acid and cryptochlorogenic acid as isomer; 3,5‐*O*‐dicaffeoylquinic acid, 3,4‐*O*‐dicaffeoylquinic acid, 4,5‐*O*‐dicaffeoylquinic acid, and 1,3‐*O*‐dicaffeoylquinic acid as isomer; hyperoside, isoquercitrin as isomer; luteoloside, astragalin as isomer; [l]{.smallcaps}‐leucine, [l]{.smallcaps}‐isoleucine as isomer; lonicerin, kaempferol‐3‐*O*‐rutinoside as isomer; they have the same precursor ion‐product ion pairs, respectively. Except for lonicerin, kaempferol‐3‐*O*‐rutinoside can be discriminated between different ion modes; other isomer reference substances were sequentially injected into QTRAP‐MS/MS to determine the compound based on the different retention time.

###### 

Optimised mass spectrometric parameters of 50 compounds

+--------+--------------------------------------------+--------------+--------------------------+---------------+--------+-------------------------+--------+------+
|        | Name                                       | CAS no.      | Formula                  | *t* ~R~ (min) | MV     | MRM (precursor→product) | DP (V) | CE   |
|        |                                            |              |                          |               |        |                         |        |      |
|        |                                            |              |                          |               |        |                         |        | (eV) |
+:=======+:===========================================+:=============+:=========================+===============+========+:========================+========+======+
| **1**  | Chlorogenic acid                           | 327--97‐9    | C~16~H~18~O~9~           | 18.75         | 354.31 | 305.01/125              | −35    | −20  |
+--------+--------------------------------------------+--------------+--------------------------+---------------+--------+-------------------------+--------+------+
| **2**  | Neochlorogenic acid                        | 906--33‐2    | C~16~H~18~O~9~           | 17.64         | 354.31 | 305.01/125              | −80    | −26  |
+--------+--------------------------------------------+--------------+--------------------------+---------------+--------+-------------------------+--------+------+
| **3**  | Cryptochlorogenic acid                     | 905--99‐7    | C~16~H~18~O~9~           | 19.86         | 354.31 | 305.01/125              | −95    | −20  |
+--------+--------------------------------------------+--------------+--------------------------+---------------+--------+-------------------------+--------+------+
| **4**  | 3,5‐*O*‐Dicaffeoylquinic acid              | 2450‐53‐5    | C~25~H~24~O~12~          | 20.15         | 516.45 | 515.1/191               | −85    | −22  |
+--------+--------------------------------------------+--------------+--------------------------+---------------+--------+-------------------------+--------+------+
| **5**  | 3,4‐*O*‐Dicaffeoylquinic acid              | 14534--61‐3  | C~25~H~24~O~12~          | 20.13         | 516.45 | 514.989/353             | −80    | −26  |
+--------+--------------------------------------------+--------------+--------------------------+---------------+--------+-------------------------+--------+------+
| **6**  | 4,5‐*O*‐Dicaffeoylquinic acid              | 57378--72‐0  | C~25~H~24~O~12~          | 20.27         | 516.45 | 515.1/191               | −75    | −24  |
+--------+--------------------------------------------+--------------+--------------------------+---------------+--------+-------------------------+--------+------+
| **7**  | 1,3‐*O*‐Dicaffeoylquinic acid              | 19870--46‐3  | C~25~H~24~O~12~          | 20.3          | 516.45 | 514.980/190.979         | −95    | −24  |
+--------+--------------------------------------------+--------------+--------------------------+---------------+--------+-------------------------+--------+------+
| **8**  | Caffeic acid                               | 331--39‐5    | C~9~H~8~O~4~             | 19.45         | 180.16 | 179.03/134.6            | −125   | −20  |
+--------+--------------------------------------------+--------------+--------------------------+---------------+--------+-------------------------+--------+------+
| **9**  | Quinic acid                                | 77--95‐2     | C~7~H~12~O~6~            | 18.75         | 192.17 | 191.099/84.981          | −195   | −28  |
+--------+--------------------------------------------+--------------+--------------------------+---------------+--------+-------------------------+--------+------+
| **10** | Protocatechuic acid                        | 99--50‐3     | C~7~H~6~O~4~             | 12.99         | 154.12 | 152.9/109               | −85    | −16  |
+--------+--------------------------------------------+--------------+--------------------------+---------------+--------+-------------------------+--------+------+
| **11** | Ferulic acid                               | 1135‐24‐6    | C~10~H~10~O~4~           | 23.89         | 194.18 | 193.017/134             | −50    | −10  |
+--------+--------------------------------------------+--------------+--------------------------+---------------+--------+-------------------------+--------+------+
| **12** | 4,5‐*O*‐Dicaffeoylquinic acid methyl ester | 114637--83‐1 | C~26~H~26~O~12~          | 29.5          | 530.47 | 529.194/135.001         | −85    | −42  |
+--------+--------------------------------------------+--------------+--------------------------+---------------+--------+-------------------------+--------+------+
| **13** | Rutin                                      | 153--18‐4    | C~27~H~30~O~16~          | 22.06         | 610.52 | 609.06/300              | −245   | −46  |
+--------+--------------------------------------------+--------------+--------------------------+---------------+--------+-------------------------+--------+------+
| **14** | Hyperoside                                 | 482--36‐0    | C~21~H~20~O~12~          | 22.74         | 464.38 | 463.003/299.9           | −160   | −36  |
+--------+--------------------------------------------+--------------+--------------------------+---------------+--------+-------------------------+--------+------+
| **15** | Luteoloside                                | 5373‐11‐5    | C~21~H~20~O~11~          | 23.03         | 448.38 | 447.117/284.963         | −300   | −36  |
+--------+--------------------------------------------+--------------+--------------------------+---------------+--------+-------------------------+--------+------+
| **16** | Luteolin                                   | 491--70‐3    | C~15~H~10~O~6~           | 29.53         | 286.24 | 285.086/132.980         | −170   | −40  |
+--------+--------------------------------------------+--------------+--------------------------+---------------+--------+-------------------------+--------+------+
| **17** | Rhoifolin                                  | 17306--46‐6  | C~27~H~30~O~14~          | 24.82         | 578.52 | 577.185/268.958         | −65    | −46  |
+--------+--------------------------------------------+--------------+--------------------------+---------------+--------+-------------------------+--------+------+
| **18** | Diosmetin                                  | 520--34‐3    | C~16~H~12~O~6~           | 30.88         | 300.26 | 298.938/283.929         | −215   | −30  |
+--------+--------------------------------------------+--------------+--------------------------+---------------+--------+-------------------------+--------+------+
| **19** | Apigenin                                   | 520--36‐5    | C~15~H~10~O~5~           | 30.74         | 270.24 | 268.8/116.9             | −129   | −40  |
+--------+--------------------------------------------+--------------+--------------------------+---------------+--------+-------------------------+--------+------+
| **20** | Kaempferol                                 | 520--18‐3    | C~15~H~10~O~6~           | 30.88         | 286.24 | 285.0/116.9             | −120   | −36  |
+--------+--------------------------------------------+--------------+--------------------------+---------------+--------+-------------------------+--------+------+
| **21** | Astragalin                                 | 480--10‐4    | C~21~H~20~O~11~          | 24.4          | 448.38 | 447.1/283.9             | −100   | −36  |
+--------+--------------------------------------------+--------------+--------------------------+---------------+--------+-------------------------+--------+------+
| **22** | Lonicerin                                  | 25694--72‐8  | C~27~H~30~O~15~          | 23            | 594.52 | 593.146/283.984         | −200   | −54  |
+--------+--------------------------------------------+--------------+--------------------------+---------------+--------+-------------------------+--------+------+
| **23** | Kaempferol‐3‐*O*‐rutinoside                | 17650--84‐9  | C~27~H~30~O~15~          | 23.59         | 610.52 | 595/287.2               | 36     | 25   |
+--------+--------------------------------------------+--------------+--------------------------+---------------+--------+-------------------------+--------+------+
| **24** | Isoquercitrin                              | 482--35‐9    | C~21~H~20~O~12~          | 22.5          | 464.38 | 463.015/300             | −180   | −36  |
+--------+--------------------------------------------+--------------+--------------------------+---------------+--------+-------------------------+--------+------+
| **25** | Sweroside                                  | 14215--86‐2  | C~16~H~22~O~9~           | 20.14         | 358.34 | 357.213/124.985         | −65    | −20  |
+--------+--------------------------------------------+--------------+--------------------------+---------------+--------+-------------------------+--------+------+
| **26** | Secologanic acid                           | 60077--46‐5  | C~16~H~22~O~10~          | 19.17         | 376.36 | 357.107/212.956         | −170   | −22  |
+--------+--------------------------------------------+--------------+--------------------------+---------------+--------+-------------------------+--------+------+
| **27** | Loganin                                    | 18524--94‐2  | C~17~H~26~O~10~          | 19.72         | 390.38 | 389.262/226.980         | −40    | −12  |
+--------+--------------------------------------------+--------------+--------------------------+---------------+--------+-------------------------+--------+------+
| **28** | Secoxyloganin                              | 58822--47‐2  | C~17~H~24~O~11~          | 21.1          | 404.37 | 403.219/120.973         | −135   | −32  |
+--------+--------------------------------------------+--------------+--------------------------+---------------+--------+-------------------------+--------+------+
| **29** | Loganin acid                               | 22255--40‐9  | C~16~H~24~O~10~          | 18.07         | 376.36 | 375.107/212.956         | −170   | −22  |
+--------+--------------------------------------------+--------------+--------------------------+---------------+--------+-------------------------+--------+------+
| **30** | Morroniside                                | 25406--64‐8  | C~17~H~26~O~11~          | 18.53         | 406.38 | 405.235/243             | −100   | −14  |
+--------+--------------------------------------------+--------------+--------------------------+---------------+--------+-------------------------+--------+------+
| **31** | Macranthoidin A                            | 140360--29‐8 | C~59~H~96~O~27~          | 30.05         | 1237.4 | 1235.464/911.43         | −235   | −48  |
+--------+--------------------------------------------+--------------+--------------------------+---------------+--------+-------------------------+--------+------+
| **32** | Dipsacoside B                              | 33289--85‐9  | C~53~H~86~O~22~          | 30.19         | 1075.2 | 1073.466/749.384        | −250   | −40  |
+--------+--------------------------------------------+--------------+--------------------------+---------------+--------+-------------------------+--------+------+
| **33** | Akebia saponin D                           | 39524--08‐8  | C~47~H~76~O~18~          | 30.32         | 929.1  | 927.445/603.34          | −155   | −50  |
+--------+--------------------------------------------+--------------+--------------------------+---------------+--------+-------------------------+--------+------+
| **34** | [l]{.smallcaps}‐Alanine                    | 56--41‐7     | C~3~H~7~NO~2~            | 1.38          | 89.09  | 90.06/44.02             | 100    | 10   |
+--------+--------------------------------------------+--------------+--------------------------+---------------+--------+-------------------------+--------+------+
| **35** | [l]{.smallcaps}‐Serine                     | 56--45‐1     | C~3~ H ~7~ NO ~3~        | 1.38          | 105.09 | 106.05/59.99            | 100    | 8    |
+--------+--------------------------------------------+--------------+--------------------------+---------------+--------+-------------------------+--------+------+
| **36** | [l]{.smallcaps}‐Proline                    | 147--85‐3    | C~5~ H ~9~ NO ~2~        | 1.65          | 115.13 | 116.07/70.02            | 68     | 10   |
+--------+--------------------------------------------+--------------+--------------------------+---------------+--------+-------------------------+--------+------+
| **37** | [l]{.smallcaps}‐Valine                     | 72--18‐4     | C~5~H~11~NO~2~           | 2.32          | 117.15 | 118.09/72.06            | 100    | 10   |
+--------+--------------------------------------------+--------------+--------------------------+---------------+--------+-------------------------+--------+------+
| **38** | [l]{.smallcaps}‐Threonine                  | 72--19‐5     | C~4~H~9~NO~3~            | 1.38          | 119.12 | 120.07/74               | 100    | 20   |
+--------+--------------------------------------------+--------------+--------------------------+---------------+--------+-------------------------+--------+------+
| **39** | [l]{.smallcaps}‐Isoleucine                 | 73--32‐5     | C~6~H~13~NO~2~           | 4.96          | 131.17 | 132.1/86.05             | 64     | 10   |
+--------+--------------------------------------------+--------------+--------------------------+---------------+--------+-------------------------+--------+------+
| **40** | [l]{.smallcaps}‐Leucine                    | 61--90‐5     | C~6~ H ~13~ NO ~2~       | 5.4           | 131.17 | 132.1/86.05             | 100    | 16   |
+--------+--------------------------------------------+--------------+--------------------------+---------------+--------+-------------------------+--------+------+
| **41** | [l]{.smallcaps}‐Aspartic acid              | 56--84‐8     | C~4~ H ~7~ NO ~4~        | 1.38          | 133.1  | 134.05/87.96            | 59     | 10   |
+--------+--------------------------------------------+--------------+--------------------------+---------------+--------+-------------------------+--------+------+
| **42** | [l]{.smallcaps}‐Glutamate                  | 138--18‐1    | C~5~H~7~NO~4~            | 1.24          | 145.11 | 147.08/83.92            | 100    | 16   |
+--------+--------------------------------------------+--------------+--------------------------+---------------+--------+-------------------------+--------+------+
| **43** | [l]{.smallcaps}‐Lysine                     | 56--87‐1     | C~6~H~14~N~2~O~2~        | 1.25          | 146.19 | 147.11/83.91            | 100    | 14   |
+--------+--------------------------------------------+--------------+--------------------------+---------------+--------+-------------------------+--------+------+
| **44** | [l]{.smallcaps}‐Histidine                  | 71--00‐1     | C~6~ H ~9~ N ~3~ O ~2~   | 1.24          | 155.15 | 156.08/110.03           | 100    | 16   |
+--------+--------------------------------------------+--------------+--------------------------+---------------+--------+-------------------------+--------+------+
| **45** | [l]{.smallcaps}‐Phenylalanine              | 63--91‐2     | C~9~ H ~11~ NO ~2~       | 13            | 165.19 | 166.1/120.05            | 100    | 14   |
+--------+--------------------------------------------+--------------+--------------------------+---------------+--------+-------------------------+--------+------+
| **46** | [l]{.smallcaps}‐Arginine                   | 74--79‐3     | C~6~H~14~N~4~O~2~        | 1.36          | 174.2  | 175.12/70.02            | 100    | 18   |
+--------+--------------------------------------------+--------------+--------------------------+---------------+--------+-------------------------+--------+------+
| **47** | Cytidine                                   | 65--46‐3     | C~9~ H ~13~ N ~3~ O ~5~  | 1.65          | 243.22 | 244.09/112              | 61     | 10   |
+--------+--------------------------------------------+--------------+--------------------------+---------------+--------+-------------------------+--------+------+
| **48** | Uridine                                    | 58--96‐8     | C~9~ H ~12~ N ~2~ O ~6~  | 4.25          | 244.2  | 244.896/113             | 10     | 13   |
+--------+--------------------------------------------+--------------+--------------------------+---------------+--------+-------------------------+--------+------+
| **49** | Adenosine                                  | 58--61‐7     | C~10~ H ~13~ N ~5~ O ~4~ | 6.73          | 267.24 | 268.1/136.07            | 86     | 23   |
+--------+--------------------------------------------+--------------+--------------------------+---------------+--------+-------------------------+--------+------+
| **50** | Inosine                                    | 58--63‐9     | C~10~ H ~12~ N ~4~ O ~5~ | 9.62          | 268.22 | 269/137.07              | 46     | 15   |
+--------+--------------------------------------------+--------------+--------------------------+---------------+--------+-------------------------+--------+------+

![Multiple‐reaction monitoring (MRM) chromatogram of 50 compounds \[Colour figure can be viewed at <http://wileyonlinelibrary.com>\]](PCA-9999-na-g001){#pca2882-fig-0001}

3.3. Analytical method validation {#pca2882-sec-0017}
---------------------------------

Validation results of the method are shown in Table [3](#pca2882-tbl-0003){ref-type="table"}. All calibration curves showed good linearity (*r* \> 0.9990) within the test range. The method also provided satisfactory sensitivity for all analytes; the LODs and LOQs ranged 0.005--139.226 ng/mL and 0.015--417.797 ng/mL, respectively. Percentage relative standard deviation (RSD%) values of intra‐day, inter‐day, repeatability, stability test of the 50 analytes were all less than 5%. The mean recoveries fell between 94.2% and 104.62%, with the RSD% values less than 4.79%, and the slope ratio values of the matrix curve to pure solution curve were between 0.94 and 1.05. All the earlier‐mentioned results demonstrated the credibility of the developed method.

###### 

Regression equation, limit of detection (LOD), limit of quantitation (LOQ), intra‐ and inter‐day precision, repeatability, stability, recovery and matrix effect of 50 compounds

  Name                                         Regression equation              *r*      Linear range (ng/mL)   LOD (ng/mL)   LOQ (ng/mL)   Precision   Repeatability   Stability   Recovery   Matrix effect          
  -------------------------------------------- -------------------------------- -------- ---------------------- ------------- ------------- ----------- --------------- ----------- ---------- --------------- ------ ------
  Chlorogenic acid                             *y* = 845*x* + 4.77e^5^          0.9999   0.604--755000          0.195         0.585         1.78        1.79            1.55        3.33       99.70           0.23   1.01
  Neochlorogenic acid                          *y* = 115*x* + 1.13e^5^          0.9992   3.01--376000           0.388         1.163         1.83        1.71            0.88        1.61       96.70           3.97   1.00
  Cryptochlorogenic acid                       *y* = 878*x* + 6.7e^3^           0.9993   0.316--79000           0.090         0.271         4.04        4.31            2.42        2.47       100.66          1.62   1.04
  3,5‐*O*‐Dicaffeoylquinic acid                *y* = 1.02e^3^ *x* + 1.41e^5^    0.9996   77.6--388000           14.483        43.449        2.63        2.79            0.72        1.62       98.70           2.65   0.98
  3,4‐*O*‐Dicaffeoylquinic acid                *y* = 602*x* + 1.45e^5^          0.9995   7.63--38200            2.094         6.282         3.95        4.39            3.14        4.94       100.67          3.65   1.02
  4,5‐*O*‐Dicaffeoylquinic acid                *y* = 483*x* + 2.1e^4^           0.9998   45--28100              7.918         23.755        3.27        3.64            1.16        1.62       98.40           2.12   1.01
  1,3‐*O*‐Dicaffeoylquinic acid                *y* = 5.78e^3^ *x* + 5.62e^4^    0.9996   42--2630               6.971         20.913        3.44        3.28            2.82        3.16       100.92          3.43   1.04
  Caffeic acid                                 *y* = 2.49e^3^ *x* + 1.69e^5^    0.9998   5.76--7200             1.169         3.506         2.86        3.17            3.29        4.83       101.17          2.05   1.03
  Quinic acid                                  *y* = 1.19e^3^ *x* + 3.05e^5^    0.9996   19.6--245000           5.131         15.392        2.73        2.38            1.69        4.18       100.20          2.48   1.05
  Protocatechuic acid                          *y* = 6.13e^3^ *x* + 1.95e^5^    0.9994   7.68--960              0.780         2.341         2.50        2.30            4.09        3.85       99.50           2.82   0.96
  Ferulic acid                                 *y* = 121*x* + 3.68e^3^          0.999    11.2--1400             2.814         8.441         4.21        3.96            3.69        3.58       102.08          4.88   0.99
  4,5‐*O*‐Dicaffeoylquinic acid methyl ester   *y* = 9.67e^3^ *x* -- 4.3e^4^    0.9996   5.6--700               1.319         3.958         3.79        4.10            1.78        1.78       98.20           3.48   0.97
  Rutin                                        y = 2.5e^3^ *x* + 3.14e^5^       0.9998   0.979--12200           0.036         0.108         2.91        3.21            3.31        3.46       95.90           3.99   1.03
  Hyperoside                                   *y* = 4.32e^3^ *x* + 1.77e^5^    0.9995   0.265--3313            0.058         0.174         1.69        1.55            3.21        3.22       100.32          3.82   1.03
  Luteoloside                                  *y* = 1.07e^3^ *x* + 1.34e^5^    1        0.664--41500           0.056         0.169         1.03        0.92            4.64        3.78       99.16           2.95   1.01
  Luteolin                                     *y* = 100*x* + 2.47e^3^          0.9995   124--15600             10.150        30.450        2.28        2.22            1.34        4.09       100.29          4.35   1.00
  Rhoifolin                                    *y* = 1.08e^4^ *x* + 572         0.9999   1.3--162               0.280         0.840         2.53        2.75            5.20        4.64       99.82           3.14   0.97
  Diosmetin                                    *y* = 1.15e^4^ *x --* 9.93e^3^   0.9993   1.72--214              0.146         0.438         1.09        0.78            4.63        2.31       100.93          2.95   0.99
  Apigenin                                     *y* = 2.17e^4^ *x --* 9.13e^4^   0.9995   25.4--318              4.188         12.563        3.54        3.83            3.39        3.47       103.09          3.98   0.98
  Kaempferol                                   *y* = 191*x* + 250               0.9997   2.02--101              0.565         1.695         4.28        4.68            3.59        3.32       101.27          3.01   0.95
  Astragalin                                   *y* = 2.17e^4^ *x* + 8.73e^4^    0.9999   0.0353--883            0.005         0.015         3.51        3.92            3.09        3.51       100.17          3.57   0.97
  Lonicerin                                    *y* = 1.11e^3^ *x* + 4.25e^3^    0.9994   22.4--14000            0.024         0.073         3.45        3.85            2.95        2.74       100.74          2.80   1.01
  Kaempferol‐3‐*O*‐rutinoside                  *y* = 3.13e^3^ *x* + 9.11e^4^    0.9999   0.632--7900            0.039         0.117         2.31        2.44            3.79        3.36       99.82           3.18   0.98
  Isoquercitrin                                *y* = 4.33e^3^ *x* + 1.4e^5^     0.9996   2.65--3310             0.195         0.584         1.68        1.54            4.97        2.91       99.68           2.12   1.02
  Sweroside                                    *y* = 34.9*x* + 1.56e^3^         0.9996   0.841--52600           0.231         0.692         3.54        3.68            3.97        4.99       101.78          2.92   1.00
  Secologanic acid                             *y* = 609*x* + 3.48e^4^          0.9999   1.45--182000           0.072         0.217         3.02        3.37            4.87        2.19       99.32           4.05   1.03
  Loganin                                      *y* = 3.95*x* + 1.72e^3^         0.999    14.1--35200            4.179         12.536        2.26        2.43            1.83        1.18       103.36          3.89   0.99
  Secoxyloganin                                *y* = 638*x* + 1.32e^5^          0.999    0.189--47400           0.052         0.157         4.19        4.67            2.47        4.68       98.42           3.14   1.02
  Loganin acid                                 *y* = 1.11e^3^ *x* -- 1.98e^5^   0.9993   441.2--22100           139.266       417.797       2.95        2.54            4.60        4.55       100.32          2.60   1.03
  Morroniside                                  *y* = 10.4*x* + 8.21e^3^         0.999    41.1--514000           7.867         23.600        2.11        1.83            4.32        3.03       101.75          4.18   0.98
  Macranthoidin A                              *y* = 193*x* + 9.76e^3^          0.9997   18.1--22600            2.989         8.967         2.72        1.94            2.43        2.70       103.97          3.66   1.01
  Dipsacoside B                                *y* = 8.94*x* + 336              0.9999   3.34--20900            0.745         2.236         2.25        2.37            3.18        3.84       99.81           0.92   1.01
  Akebia saponin D                             *y* = 6.02*x* + 8.06e^3^         0.9996   16.6--207000           1.539         4.618         3.10        1.65            1.46        1.05       102.90          4.10   0.94
  [l]{.smallcaps}‐Alanine                      *y* = 1.43e^3^ *x* + 1.78e^4^    0.9997   8.47--10600            2.228         6.684         3.07        2.60            4.50        3.43       101.09          4.66   1.03
  [l]{.smallcaps}‐Serine                       *y* = 351*x* + 5.93e^4^          0.9997   9.16--11500            1.342         4.027         2.71        2.54            3.31        3.40       99.84           1.96   1.02
  [l]{.smallcaps}‐Proline                      *y* = 1.77e^3^ *x* + 3.04e^4^    0.9996   0.381--23800           0.093         0.279         2.75        2.86            2.84        1.13       102.36          2.19   1.01
  [l]{.smallcaps}‐Valine                       *y* = 6.36e^3^ *x* + 2.17e^5^    0.9995   2.51--1570             0.215         0.644         2.96        3.19            1.49        3.33       98.52           3.85   1.04
  [l]{.smallcaps}‐Threonine                    *y* = 1.75e^3^ *x* -- 9.1e^4^    0.9996   111--13900             22.325        66.975        2.83        1.46            3.20        2.83       96.47           4.28   0.97
  [l]{.smallcaps}‐Isoleucine                   *y* = 5.15e^3^ *x* + 1.92e^5^    0.9998   2.88--3600             0.422         1.265         0.67        0.63            1.27        2.54       99.49           2.45   1.00
  [l]{.smallcaps}‐Leucine                      *y* = 9.64e^3^ *x* + 4.72e^5^    0.9997   3.38--4230             0.711         2.134         1.21        1.28            4.23        3.05       103.97          2.36   1.01
  [l]{.smallcaps}‐Aspartic acid                *y* = 660*x* + 2.38e^4^          0.9991   4.6--57500             0.835         2.506         1.49        1.66            4.18        4.27       99.27           2.96   0.96
  [l]{.smallcaps}‐Glutamate                    *y* = 1.64e^3^ *x* -- 2.82e^5^   0.9998   474--29600             136.177       408.530       0.69        0.74            1.71        1.53       96.93           3.96   1.04
  [l]{.smallcaps}‐Lysine                       *y* = 2.32e^3^ *x* -- 2.01e^5^   0.9993   147--12600             36.781        110.342       0.58        0.65            2.15        2.20       95.67           3.73   0.99
  [l]{.smallcaps}‐Histidine                    *y* = 7.11e^3^ *x* + 1.65e^5^    0.9999   59.1--7390             7.656         22.968        1.67        1.45            3.55        3.62       104.62          4.79   1.05
  [l]{.smallcaps}‐Phenylalanine                *y* = 1.7e^4^ *x* + 2.55e^5^     0.9997   25.6--3200             0.550         1.650         1.78        1.28            3.16        2.36       97.56           3.06   1.03
  [l]{.smallcaps}‐Arginine                     *y* = 6.54e^3^ *x* + 1.21e^5^    0.9996   0.241--1510            0.043         0.128         1.25        1.19            4.54        4.50       100.17          1.98   1.00
  Cytidine                                     *y* = 4.72e^4^ *x* -- 1.94e^4^   0.9995   1.84--230              0.496         1.488         3.39        3.20            4.69        3.99       94.20           3.90   1.01
  Uridine                                      *y* = 861*x* + 7.0e^3^           0.9997   40.4--5050             7.124         21.372        3.20        3.53            4.19        3.26       100.95          2.55   1.01
  Adenosine                                    *y* = 5.28e^4^ *x* + 3.05e^5^    0.9994   6.31--789              0.945         2.834         1.45        1.41            1.89        3.29       97.76           3.70   0.98
  Inosine                                      *y* = 7.98e^3^ *x* + 2.12e^4^    0.9991   8.78--220              1.847         5.542         1.73        1.87            3.95        3.93       101.52          4.10   0.95

3.4. Simultaneous quantitation of constituents of sample {#pca2882-sec-0018}
--------------------------------------------------------

Contents of 50 constituents were determined using UFLC‐QTRAP‐MS/MS method in 35 batches of samples. The contents of quantitative determination are shown in Supporting Information Table [S1](#pca2882-supitem-0002){ref-type="supplementary-material"}. Our data from different samples elucidated that the chemicals were significantly different between LJF and LF. The contents of protocatechuic acid, rutin, loganin, and morroniside were too low to be detected in LF. The flavonoids of luteoloside, lonicerin, kaempferol‐3‐*O*‐rutinoside and the iridoids of sweroside, secologanic acid were also in low contents compared with LJF. However, the contents of macranthoidin A, akebia saponin D and dipsacoside B were much higher than LJF. Among them, dipsacoside B reached up to 70687.6 μg/g, therefore, it was considered as a characteristic component of LF in current Chinese Pharmacopoeia. Content percentages of six types of component (organic acids, flavonoids, iridoids, saponins, amino acids, and nucleosides) in 35 batches of samples are shown in Figure [2](#pca2882-fig-0002){ref-type="fig"}. The results indicated that the contents have a significant variation in different samples. It is clear that the bioactive components of organic acids account for the largest proportion. Noteworthy, the literature[33](#pca2882-bib-0033){ref-type="ref"}, [34](#pca2882-bib-0034){ref-type="ref"} also suggest that phenolic acids are regarded as one of the main anti‐inflammatory and anti‐bacterial active ingredients. This conclusion might explain the efficacy of "qing‐re‐jie‐du" of LJF and LF. Moreover, regardless of the organic acid, flavonoids or iridoids, the average contents in the flower buds were higher than that of the flowers.

![Content percentages of six types of component in 35 batches of samples \[Colour figure can be viewed at <http://wileyonlinelibrary.com>\]](PCA-9999-na-g002){#pca2882-fig-0002}

3.5. Multivariate statistical analysis of samples {#pca2882-sec-0019}
-------------------------------------------------

### 3.5.1. PCA and PLS‐DA of samples {#pca2882-sec-0020}

To classify and differentiate LJF and LF in chemical composition, PCA and PLS‐DA were performed. The PCA scores plot are displayed in Figure [3](#pca2882-fig-0003){ref-type="fig"}(a). The two principal components were set to PC1 and PC2 as variables. Obviously, the samples were divided into two groups. LJF was distributed over the PC1 negative axis; LF was scattered in the PC1 positive axis. Furthermore, the PC1 and PC2 described 69.3% and 13.8% of variability between samples, respectively. This indicated that LJF and LF were significantly different in chemical composition. PLS‐DA was used to extend to find out the constituents contributing to the differences between LJF and LF. In the PLS‐DA scores plot (Figure [3](#pca2882-fig-0003){ref-type="fig"}b), LJF and LF were separated into two clusters; the flower buds and flowers of LJF also were divided. The flowers were distributed over the PC2 positive axis, the flower buds were mostly scattered in the PC2 negative axis. In the plot PLS‐DA loading (Figure [3](#pca2882-fig-0003){ref-type="fig"}c) and the variable influence on projection (VIP) (Figure [3](#pca2882-fig-0003){ref-type="fig"}d), the large load value (VIP \> 1) can be regarded as a marker component that contributes greatly to the classification of these samples. [l]{.smallcaps}‐Proline, [l]{.smallcaps}‐serine, [l]{.smallcaps}‐glutamate, chlorogenic acid, 1,3‐*O*‐dicaffeoylquinic acid, protocatechuic acid, secoxyloganin, secologanic acid, morroniside, macranthoidin A and dipsacoside B could be considered as chemical markers for the sample classification.

![Multivariate statistical analysis of 35 batches of samples. (a) Principal component analysis (PCA) scores plot: triangles represent Lonicerae Flos (LF) samples, squares represent Lonicerae Japonicae Flos (LJF) samples. (b) Partial least squares discriminant analysis (PLS‐DA) scores plot: triangles represent LF samples, yellow squares represent flowers samples, blue squares represent flower buds samples (LJF). (c) PLS‐DA loading plot: each green squares represent one compound. (d) VIP \[Colour figure can be viewed at <http://wileyonlinelibrary.com>\]](PCA-9999-na-g003){#pca2882-fig-0003}

### 3.5.2. GRA of samples {#pca2882-sec-0021}

GRA was carried out to evaluate the quality of samples based on the contents of 50 constituents. Grey comprehensive evaluation values (*r* ~*i*~) and quality ranking are listed in Table [4](#pca2882-tbl-0004){ref-type="table"}. It could be seen that the quality of LJF is better than LF; the quality ranking of flower buds mostly ahead of the flowers, except for samples 11, 15 and 17. It may be related to different habits and origin. In general, the quality of the flower buds is superior to that of the flowers. A previous study has also shown that the flower buds have the highest medical value.[35](#pca2882-bib-0035){ref-type="ref"} Our results add further support for this conclusion.

###### 

Quality sequencing of samples

  Sample   *r* ~*i*~   Quality ranking   Sample   *r* ~*i*~   Quality ranking
  -------- ----------- ----------------- -------- ----------- -----------------
  1        0.3567      33                19       0.4321      2
  2        0.3778      25                20       0.4130      8
  3        0.3693      31                21       0.4088      11
  4        0.3977      18                22       0.3767      26
  5        0.3752      27                23       0.4094      10
  6        0.3745      28                24       0.3676      32
  7        0.3897      21                25       0.3705      29
  8        0.4070      13                26       0.4202      4
  9        0.3865      22                27       0.4134      7
  10       0.4018      16                28       0.3947      19
  11       0.3809      23                29       0.3695      30
  12       0.4479      1                 30       0.3789      24
  13       0.4168      5                 31       0.4050      14
  14       0.4124      9                 32       0.4032      15
  15       0.3935      20                33       0.3548      35
  16       0.4142      6                 34       0.3550      34
  17       0.4083      12                35       0.3978      17
  18       0.4247      3                                      

In summary, a sensitive and comprehensive method employing UFLC‐QTRAP‐MS/MS coupled with multivariate statistical analyses was established to evaluate the quality of LJF and LF. A total number of 50 constituents, including 12 organic acids, 12 flavonoids, 6 iridoids, 3 saponins, 13 amino acids, and 4 nucleosides were simultaneously assayed in LJF and LF. Using either PCA or PLS‐DA, it was clear to differentiate LJF and LF, and the sample classification is closely related to 11 different chemical constituents, such as, [l]{.smallcaps}‐proline, [l]{.smallcaps}‐serine, [l]{.smallcaps}‐glutamate, chlorogenic acid, 1,3‐*O*‐dicaffeoylquinic acid, protocatechuic acid, secoxyloganin, secologanic acid, morroniside, macranthoidin A and dipsacoside B. The GRA assay and the data of content determination also demonstrated the quality of LJF was better than that of LF, and that of the flower buds was superior to the flowers. Therefore, we suggest that LJF should be harvested at the bud stage in order to improve the clinical medicinal value. In addition, organic acids were the main components in LJF and LF. Overall, our study not only established a method of simultaneous determination of multiple types of bioactive constituents of LJF and LF, but provided comprehensive information on the quality control of them. The developed method is conducive to distinguish orthologues or paralogues of them, and provide the support for "heterologous effects".
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###### 

Figure S1 Chemical structures of 50 compounds in Lonicerae Japonicae Flos (LJF) and Lonicerae Flos (LF)

###### 

Click here for additional data file.

###### 

Table S1 Contents (ug/g) of 50 constituents in samples of Lonicerae Japonicae Flos (LJF) and Lonicerae Flos (LF)

###### 

Click here for additional data file.
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